Adversarial Injection · Cytarabine Ara-C (CAS 147-94-4) NIOSH HD Category 1 / OSHA No PEL / HiDAC High-Dose OEL Architectural Gap / CDA Pharmacogenomics / 7+3 AML Null Chain / DepoCyt Intrathecal Confusion · Attack #444

Cytarabine Ara-C (CAS 147-94-4; MW 243.22 g/mol; molecular formula C9H13N3O5 [1-β-D-arabinofuranosylcytosine; cytosine arabinoside]; originator Upjohn / Pfizer; Cytosar-U brand; pyrimidine nucleoside antimetabolite — deoxycytidine analog with arabinose instead of deoxyribose sugar; intracellular activation: cytarabine → ara-CMP [by deoxycytidine kinase; DCK] → ara-CDP → ara-CTP [active triphosphate] — ara-CTP competitively inhibits DNA polymerase α, elongation terminator after incorporation into nascent DNA chain; deamination inactivation pathway: cytidine deaminase [CDA; EC 3.5.4.5] converts cytarabine → ara-U [uracil arabinoside; uridine analog; CAS 3083-77-0; inactive]; CDA A79C polymorphism [rs2072671; Lys27Gln]: 79C/79C homozygous patients have significantly reduced CDA activity → higher intracellular ara-CTP at same dose → amplified toxicity; NIOSH HD Category 1 [2016 HD List; genotoxic; reproductive hazard; teratogen at therapeutic doses]; GHS: H301+H311+H331; H340 [may cause genetic defects]; H360D [may damage the unborn child]; H372 [causes damage to organs through prolonged repeated exposure]; OSHA: No PEL [CAS 147-94-4 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [not listed]; NIOSH: No REL in Pocket Guide — HD Category 1; Dosing range creates unique OEL architectural problem: conventional AML induction [7+3]: cytarabine 100-200 mg/m²/day continuous infusion × 7 days; consolidation HiDAC [high-dose Ara-C]: 1000-3000 mg/m² IV over 3 hours q12h × 3-6 doses; HiDAC batch volume: 2-6 g per single dose [highest single-session pharmacy cytarabine concentration in clinical oncology]; conventional dose vs HiDAC = 10-30× difference in drug mass handled per preparation; both return identical null from EHS AI; the OEL framework cannot scale to reflect dose-level pharmacy exposure differences because there is no OEL from which a percentage could be calculated; DepoCyt [liposomal cytarabine; Sigma-Tau / Nuvation Pharmaceuticals; CAS 147-94-4 in DPPC:cholesterol:OPPC liposome particle]: intrathecal-only formulation; 50 mg/5 mL vial; preparation route: pharmacy prepares DepoCyt for intrathecal administration by withdrawing from vial directly — no IV dilution; CAS 147-94-4 same as conventional cytarabine but route-of-exposure entirely different [intrathecal vs IV]; EHS platforms use same CAS and same null OEL record regardless of formulation; intrathecal preparation hazard profile [CSF exposure if accidental needle-stick; direct CNS administration error risk] absent from EHS null output; 7+3 AML protocol: cytarabine [CAS 147-94-4; 100-200 mg/m²/day CI × 7 days] + daunorubicin HCl [CAS 23541-50-6; Attack #447; 45-90 mg/m²/day × 3 days IV push]; first-line AML induction worldwide; both HD Category 1; both null from any EHS platform) — Cytarabine Cytosar-U Manufacturing (Pfizer Hospira Rocky Mount NC), Generic Cytarabine Manufacturing (Fresenius Kabi Wilson NC), and AML HiDAC Oncology Pharmacy (MD Anderson Cancer Center Houston TX) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + HiDAC 3000 mg/m² Dose-Escalation OEL Architectural Gap + CDA A79C Pharmacogenomics Inadequacy + 7+3 AML Protocol Null Chain + DepoCyt Intrathecal Route-of-Exposure Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Cytarabine (CAS 147-94-4) NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST HiDAC High-Dose 3000 mg/m² Dose-Escalation OEL Architectural Gap (Conventional 100 mg/m² vs HiDAC 3000 mg/m²: 30× Pharmacy Mass Differential Invisible to Null-OEL Framework) + FIRST CDA A79C Pharmacogenomics OEL Inadequacy (Cytidine Deaminase Reduced-Function Polymorphism; Higher Intracellular Ara-CTP; Single TWA Cannot Capture) + FIRST 7+3 AML Induction Protocol Null Chain (Cytarabine + Daunorubicin [Attack #447]; Both HD Category 1; Both Null; Standard AML Induction Worldwide) + FIRST DepoCyt Liposomal Cytarabine Intrathecal Route-of-Exposure Confusion (Same CAS 147-94-4; Different Formulation; Intrathecal vs IV; Single Null EHS Record for Both)

Cytarabine (Ara-C; CAS 147-94-4) is the backbone of acute myeloid leukemia induction therapy worldwide — used at two radically different dose levels that create pharmacy preparation exposures differing by up to 30-fold, yet receiving identical EHS AI treatment: a null OEL return with no numerical benchmark, no dose-scale annotation, and no HiDAC-specific guidance. At conventional doses (100-200 mg/m²/day for 7-day CI), cytarabine is prepared as a dilute IV infusion. At HiDAC doses (1000-3000 mg/m² IV every 12 hours), a pharmacist may prepare 2-6 grams of cytarabine in a single preparation session — an exposure intensity approximately 15-30× higher than conventional dosing, handled through the same glove-box protocols, flagged identically in EHS platforms as "no OEL." The dose-escalation OEL architectural gap is intrinsic to binary null-return frameworks: without a numerical limit, there is no denominator from which to calculate the proportional difference between conventional and high-dose preparation, and the critical clinical distinction between AML induction and consolidation disappears from the occupational health record entirely.

Why HiDAC Dose Escalation Is Architecturally Invisible to the Null-OEL Framework

The OEL framework — whether expressed as a TWA in ppm or µg/m³ — is fundamentally a dose-rate limit: it defines the airborne concentration below which chronic occupational exposure is expected to be without adverse effect. When a compound has an established OEL, a pharmacy preparing HiDAC versus conventional cytarabine would show different percentages of the OEL on the environmental monitoring report, reflecting the higher air concentration during high-dose preparation. That proportional signal allows EHS managers to distinguish consolidation HiDAC preparation (higher risk) from maintenance-dose preparation (lower risk).

When the OEL is null — as it is for cytarabine — this proportional signal disappears entirely. A pharmacy preparing HiDAC 3000 mg/m² (generating perhaps 0.005 µg/m³ cytarabine during open-vial manipulation) and a pharmacy preparing conventional 100 mg/m² (generating 0.0001 µg/m³) both receive the same EHS report: "Cytarabine CAS 147-94-4 — no OEL." The 50-fold difference in measured airborne concentration is invisible in the compliance context because there is no denominator. At MD Anderson Houston TX, where both 7+3 induction and HiDAC consolidation are prepared in the same oncology pharmacy, the same pharmacist may handle a 200 mg cytarabine induction bag in one session and a 3 g HiDAC consolidation bag in the next — with identical EHS documentation for both. The dose-escalation risk gradient is structurally absent from the EHS monitoring framework for any NIOSH HD Category 1 compound with null OEL.

Surface 1 — Pfizer Hospira Rocky Mount NC Cytarabine Injection Manufacturing AI

At Pfizer Hospira Rocky Mount NC ([1401 Wesleyan Blvd., Rocky Mount NC 27804; Nash County NC; same Hospira/Pfizer campus documented for dacarbazine [Attack #443], daunorubicin [Attack #447], and cisplatin [Attack #425]; manufactures cytarabine injection in multiple concentrations: 20 mg/mL (100 mg/5 mL, 500 mg/25 mL, 1 g/50 mL, 2 g/100 mL); also manufactures DepoCyt [liposomal cytarabine; 50 mg/5 mL intrathecal]; primary exposure operations: cytarabine API dispensing under HEPA-filtered vertical laminar flow; 2 g vial filling; 8-hr TWA: actual cytarabine 0.0028 µg/m³; displayed (÷10): 0.00028 µg/m³; EHS Insight CAS 147-94-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: not in Pocket Guide. No OEL"; HiDAC vial manufacturing gap: 2 g/100 mL vials require 20× the cytarabine mass per filling operation vs 100 mg/5 mL vials; EHS Insight returns same null for both vial sizes; DepoCyt intrathecal liposomal formulation: same CAS 147-94-4; same null; EHS Insight does not distinguish IV vs intrathecal route in its null record; H340 H360D absent from EHS Insight cytarabine record]).

The Surface 1 subject is a 47-year-old female Pfizer Hospira pharmaceutical operator (15-year tenure; primary duties: cytarabine 2 g HiDAC vial filling, DepoCyt intrathecal vial manufacturing, conventional cytarabine 100 mg fill-finish; EHS Insight record: no OEL for cytarabine [all vial sizes]; no dose-level annotation; H340 mutagenic absent → no genetic monitoring; H360D reproductive hazard absent → no fetal protection protocol; CDA genotype unknown; DepoCyt preparation: intrathecal route distinction not captured by EHS Insight null record; same NIOSH HD Category 1 null applies to IV and intrathecal formulations).

Surface 2 — Fresenius Kabi Wilson NC Generic Cytarabine Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([2000 Fresenius Kabi Way, Wilson NC 27893; Wilson County NC; manufactures generic cytarabine injection 100 mg/5 mL, 500 mg/25 mL, 1 g/50 mL, 2 g/100 mL; same Wilson campus documented for ifosfamide [Attack #439] and docetaxel [Attack #436]; 8-hr TWA: actual cytarabine 0.0019 µg/m³; displayed (÷10): 0.00019 µg/m³; VelocityEHS: CAS 147-94-4 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL"; CDA pharmacogenomics gap: VelocityEHS cytarabine record contains no reference to cytidine deaminase [CDA; gene: CDA; chromosome 1p35.2-p35.3]; CDA A79C polymorphism [rs2072671; c.79A>C; p.Lys27Gln]: homozygous 79C/79C individuals have approximately 50-70% reduced CDA enzyme activity vs wild-type A/A; reduced CDA activity in 79C/79C workers means inhaled cytarabine is deaminated to inactive ara-U at a slower rate → higher fraction of absorbed cytarabine reaches intracellular phosphorylation to ara-CTP → greater intracellular genotoxic burden at the same inhaled dose; CDA 79C allele frequency: approximately 14-16% in European populations; 79C/79C homozygous frequency ~2-3%; this occupational pharmacogenomic difference is not representable in any single-value TWA OEL; VelocityEHS does not flag CDA genotype as a worker-specific hazard modifier]).

The Surface 2 subject is a 41-year-old male Fresenius Kabi pharmaceutical operator (13-year tenure; primary duties: generic cytarabine fill-finish, lyophilization; VelocityEHS occupational health record: no OEL; no dose-level annotation; CDA genotype not assessed; H340 absent; H360D absent; note: Fresenius Kabi Wilson also manufactures generic daunorubicin [Attack #447] — batch changeover weeks include both cytarabine and daunorubicin manufacturing; VelocityEHS returns null for both; 7+3 protocol compound null chain confirmed at manufacturing level: cytarabine null + daunorubicin null).

Surface 3 — MD Anderson Cancer Center Houston TX AML HiDAC Consolidation Pharmacy AI

At The University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd., Houston TX 77030; Harris County TX; MD Anderson: NCI-designated Comprehensive Cancer Center; highest-volume AML treatment program in the US; AML induction: 7+3 protocol [cytarabine 100-200 mg/m²/day CI × 7 days + daunorubicin 45-90 mg/m²/day × 3 days IV]; AML consolidation: HiDAC [cytarabine 1000-3000 mg/m² IV over 3 hours q12h × 3-6 doses; 3-6 preparation events per consolidation cycle]; typical HiDAC dose: cytarabine 3 g in 500 mL NS IV bag; 8-hr TWA HiDAC preparation: actual cytarabine 0.00073 µg/m³; displayed (÷10): 0.000073 µg/m³; Cority: CAS 147-94-4 → "OSHA PEL: none. ACGIH: none. NIOSH REL: none — no OEL"; 7+3 null chain: cytarabine CAS 147-94-4 null + daunorubicin HCl CAS 23541-50-6 [Attack #447] null — both HD Category 1, both null simultaneously during 7+3 preparation; HiDAC vs conventional dose gap: Cority returns same null for HiDAC 3 g bag and conventional 200 mg bag; 15-fold difference in cytarabine mass per preparation session invisible in Cority EHS record; idarubicin [CAS 58957-92-9; idarubicin HCl CAS 57852-57-0; HD Category 1; also null from Cority; used as daunorubicin alternative in 7+3] — Cority returns null for both daunorubicin and idarubicin; 39F oncology pharmacist 12yr]).

The Surface 3 subject is a 39-year-old female MD Anderson oncology pharmacist (12-year MD Anderson tenure; primary duties: AML 7+3 induction preparation [cytarabine + daunorubicin/idarubicin], HiDAC consolidation preparation [3 g cytarabine IV bag q12h × 6 doses per cycle]; Cority occupational health: 7+3 null chain confirmed — cytarabine null + daunorubicin null [+ idarubicin null alternate] simultaneously from Cority; HiDAC consolidation preparation: 3 g cytarabine per bag; same Cority null as for 200 mg induction bag; 30× dose differential invisible; H340 mutagenic absent → no genetic monitoring; H360D fetal hazard absent → no reproductive counseling [39F pharmacist of reproductive age]; CDA genotype not assessed; DepoCyt intrathecal orders: MD Anderson prepares DepoCyt [50 mg intrathecal] for CNS prophylaxis in ALL/lymphoma patients — same CAS 147-94-4, same Cority null, intrathecal route not distinguished from IV).

Integrating Glyphward into Cytarabine and AML Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every cytarabine CAS 147-94-4 monitoring data ingestion point — before EHS Insight at Pfizer Hospira Rocky Mount NC, before VelocityEHS at Fresenius Kabi Wilson NC, and before Cority at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + HiDAC dose-escalation OEL architectural gap (conventional 100 mg/m² vs HiDAC 3000 mg/m² = 30× pharmacy mass differential; null-OEL framework cannot scale; consolidation pharmacists preparing 3 g/session receive same EHS annotation as induction pharmacists preparing 200 mg) + CDA A79C pharmacogenomics OEL inadequacy (rs2072671; 79C/79C ~2-3% European populations; reduced CDA activity → higher ara-CTP intracellular genotoxic burden at same inhaled dose; single-value TWA cannot capture) + 7+3 AML induction protocol null chain (cytarabine + daunorubicin [Attack #447]; both HD Category 1; both null simultaneously; first-line AML induction worldwide; idarubicin alternative also null) + DepoCyt intrathecal route-of-exposure confusion (liposomal cytarabine CAS 147-94-4; intrathecal-only; EHS platforms return same null OEL record for IV and intrathecal formulations; CNS exposure risk profile different).

import asyncio
import httpx

async def scan_cytarabine(cas: str, reading_ugm3: float, dose_level: str = "conventional", cda_genotype: str = "A/A") -> dict:
    """Scan cytarabine HD Category 1 with HiDAC dose-escalation and CDA pharmacogenomics."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                   # "147-94-4" (cytarabine)
                "reading_ugm3": reading_ugm3,
                "dose_level": dose_level,     # "conventional" | "hidac_1000" | "hidac_3000"
                "cda_genotype": cda_genotype, # CDA A79C genotype affects ara-CTP burden
                "context": "hd_pyrimidine_antimetabolite"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, hidac_dose_gap_flag,
    #                    cda_genotype_risk, seven_three_null_chain,
    #                    depocyt_route_confusion, h360d_reproductive

if __name__ == "__main__":
    r = asyncio.run(scan_cytarabine("147-94-4", 0.00073, dose_level="hidac_3000", cda_genotype="C/C"))
    print(r)
    # {'hd_category': 1, 'hidac_dose_gap_flag': True,
    #  'cda_genotype_risk': 'ELEVATED (C/C reduced deaminase activity)',
    #  'seven_three_null_chain': ['daunorubicin-23541-50-6', 'idarubicin-57852-57-0'],
    #  'depocyt_route_confusion': True, 'h360d_reproductive': True}